Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, February 14, 2021

Eosinophilic Sialodochitis: A Type of Chronic Obstructive Sialadenitis Related to Allergy

xlomafota13 shared this article with you from Inoreader

Objectives

To investigate the clinical, laboratory, radiological, histopathological, and immunohistochemical features, and the expression of allergy‐related cytokines in eosinophilic sialodochitis (ES).

Methods

Thirty‐eight patients diagnosed with chronic obstructive sialadenitis (COS) who had undergone glandular excision or incisional biopsy were enrolled. Seventeen patients with comorbid atopic disease and increased ductal tissue eosinophils comprised the ES group, while 21 patients comprised the COS group. The clinicopathological features and allergy‐related cytokine expression were compared between groups.

Results

The ES group frequently involved multiple, bilateral major salivary glands, and the number of glands was significantly greater than the COS group (2.8 ± 1.1 vs. 1.2 ± 0.4, P < .001). Serum immunoglobulin (Ig) E was elevated in 91% of patients in ES group (419 ± 357 kU/L) and peripheral blood eosinophil was significantly greater compared with the COS group (7.6% ± 4.6% vs. 2.5% ± 1.4%, P < .001). Histologically, eosinophil infiltration in ES group was observed around the main and interlobular ducts (50 ± 39/high power field [HPF]). Follicular hyperplasia (76%), epithelial mucous metaplasia (82%), and mucus plugs with eosinophils (41%) were observed. IgE‐positive cell count was 20.7 ± 18.3/HPF and tryptase‐positive mast cell count was 23.5 ± 15.1/HPF, which was significantly greater than the respective cell counts in COS group, which mainly infiltrated around the ducts. The levels of interleukin‐4, interleukin‐1 3, and eotaxin in tissue were significantly greater in ES than the COS group.

Conclusions

The clinicopathological characteristics of ES are significantly different from COS and ES might have an allergy‐related pathogenesis.

Level of Evidence

4 Laryngoscope, 131:E800–E806, 2021

View on the web

No comments:

Post a Comment